Shigella Infections in the United States, 1974-1980

Mj, Blaser; Ra, Pollard; Ra, Feldman

doi:10.1093/infdis/147.4.771

Cited by 39 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It then disappeared for unknown reasons, although S. dysenteriae type 1 reappeared as an epidemic in 1968 in Central America, Asia and Africa (Gangarosa et al, 1970; Pal, 1984; Rahaman et al, 1975; Ries et al, 1994). Later, the prevalence of S. dysenteriae was replaced by S. flexneri , which in turn was gradually replaced by S. sonnei (Kostrzewski, 1968; Martin, Pollard & Feldman, 1983). Occurrences of S. boydii have meanwhile been reported on the Indian subcontinent and Latin America, but have been infrequent in other regions of the world (Fernandez-Prada et al, 2004; Niyogi, 2005; Rolfo et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and potential of phage therapy against multidrug resistantShigellaspp.

Tang

Biswas

Tan

et al. 2019

PeerJ

View full text Add to dashboard Cite

Shigella-infected bacillary dysentery or commonly known as Shigellosis is a leading cause of morbidity and mortality worldwide. The gradual emergence of multidrug resistantShigellaspp. has triggered the search for alternatives to conventional antibiotics. Phage therapy could be one such suitable alternative, given its proven long term safety profile as well as the rapid expansion of phage therapy research. To be successful, phage therapy will need an adequate regulatory framework, effective strategies, the proper selection of appropriate phages, early solutions to overcome phage therapy limitations, the implementation of safety protocols, and finally improved public awareness. To achieve all these criteria and successfully apply phage therapy against multidrug resistant shigellosis, a comprehensive study is required. In fact, a variety of phage-based approaches and products including single phages, phage cocktails, mutated phages, genetically engineered phages, and combinations of phages with antibiotics have already been carried out to test the applications of phage therapy against multidrug resistantShigella.This review provides a broad survey of phage treatments from past to present, focusing on the history, applications, limitations and effective solutions related to, as well as the prospects for, the use of phage therapy against multidrug resistantShigellaspp. and other multidrug resistant bacterial pathogens.

show abstract